Welcome to our dedicated page for Aptinyx news (Ticker: APTX), a resource for investors and traders seeking the latest updates and insights on Aptinyx stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aptinyx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aptinyx's position in the market.
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company focused on therapies for brain disorders, announced its participation in two upcoming conferences. CEO Norbert Riedel will join the Pain & Addiction Panel at the 4th Annual Neuroscience Innovation Forum on April 29, 2021. Additionally, the company will hold one-on-one investor meetings at the 7th Annual Truist Securities Life Sciences Summit on May 4-5, 2021. Aptinyx is developing novel NMDA receptor modulators targeting conditions like chronic pain and cognitive impairment.
Aptinyx Inc. (Nasdaq: APTX) has resumed patient screening for its Phase 2 study of NYX-458, aimed at treating mild cognitive impairment and mild dementia linked to Parkinson’s disease and dementia with Lewy bodies. Approximately 100 patients will participate in this double-blind study, evaluating daily oral doses of NYX-458 over 12 weeks. The company plans to announce results in the second half of 2022. NYX-458 targets NMDA receptor dysfunction, a key factor in cognitive deficits related to these conditions, with promising preclinical data supporting its potential benefits.
Aptinyx Inc. (Nasdaq: APTX) reported its fourth quarter and full year 2020 financial results, highlighting a cash balance of $141 million, which is expected to sustain operations into 2023. The company is advancing its clinical pipeline of NMDA receptor modulators amidst the pandemic, with several Phase 2 studies expected to report results within the next 24 months. Revenue for 2020 totaled $1.6 million, reflecting a decrease due to the conclusion of a research collaboration with Allergan. The net loss for the year was $50.1 million, an improvement from $57.4 million in 2019.
Aptinyx Inc. (Nasdaq: APTX) will host a conference call and live webcast on March 24, 2021, at 5:00 p.m. ET to report its fourth-quarter and full-year 2020 financial results. The call will also discuss recent business highlights. Interested participants can join by calling (833) 772-0394 domestically or (236) 738-2205 internationally, using conference ID 4846816. A replay will be available for 30 days on Aptinyx’s website. The company focuses on developing therapies for brain and nervous system disorders and has three product candidates in clinical development.
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company, announced its participation in two investor conferences. The Cowen 41st Annual Health Care Conference will feature CEO Norbert Riedel in the Neuropsychiatry Panel discussion on March 1, 2021. Additionally, the company will engage in one-on-one investor meetings at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The neuropsychiatry discussion will be available for viewing on Aptinyx’s website for 30 days post-event. Aptinyx focuses on developing therapies for brain and nervous system disorders.
Aptinyx Inc. (Nasdaq: APTX) announced its participation in a virtual fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, at 10:40 a.m. EST. The event will be webcast live and available for 30 days on the company’s website. Aptinyx is focused on developing therapies for brain and nervous system disorders, utilizing a unique mechanism to modulate NMDA receptors. The company has three clinical candidates targeting chronic pain, PTSD, and cognitive impairment linked to Parkinson’s disease.
Aptinyx Inc. (Nasdaq: APTX) recently published a review article in Medicine in Drug Discovery detailing the potential therapeutic benefits of its NMDA receptor modulator, NYX-2925, in treating chronic centralized pain. The data from multiple preclinical models demonstrated robust activity, suggesting a promising safety and efficacy profile. NYX-2925 has shown clear signals of effectiveness in two Phase 2 studies and is advancing toward completion in the first half of 2022. The FDA has granted it Fast Track designation for neuropathic pain treatment.
Aptinyx Inc. (Nasdaq: APTX) announced its participation in the virtual H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The fireside chat will be available on-demand starting 6:00 AM ET on January 11, through the H.C. Wainwright conference portal. Additionally, a webcast will be accessible on the 'Events and Presentations' page of the company's website, archived for 30 days post-event. Aptinyx focuses on developing therapies for brain and nervous system disorders, with three product candidates in clinical development.
Aptinyx Inc. (Nasdaq: APTX) has resumed patient recruitment for its Phase 2 study of NYX-2925, targeting painful diabetic peripheral neuropathy (DPN). The study, which was halted due to COVID-19, aims to enroll approximately 200 patients and evaluate the drug's efficacy and safety. NYX-2925, an oral NMDA receptor modulator, has shown promise in alleviating chronic pain. The primary endpoint is the change in average daily pain score over 12 weeks. Top-line data is anticipated in the first half of 2022, alongside concurrent research in fibromyalgia.
Aptinyx Inc. (Nasdaq: APTX) announced its participation in the 39th Annual J.P. Morgan Healthcare Conference, where CEO Norbert Riedel will present virtually on January 14, 2021, at 9:10 a.m. Eastern Time. A live webcast will be available on the company's website, with an archive accessible for 30 days post-event. Aptinyx focuses on developing therapies for brain and nervous system disorders, utilizing a unique platform targeting NMDA receptors to enhance synaptic plasticity. The company has three clinical candidates including treatments for chronic pain and cognitive impairment.
